<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730431</url>
  </required_header>
  <id_info>
    <org_study_id>2355-002</org_study_id>
    <secondary_id>IDX-08C-002</secondary_id>
    <nct_id>NCT00730431</nct_id>
  </id_info>
  <brief_title>Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002)</brief_title>
  <official_title>A Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IDX184 After Oral Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain single dose safety and pharmacokinetic (PK) data of
      IDX184 in humans. No formal hypotheses are to be tested in this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants experiencing serious adverse events (SAEs)</measure>
    <time_frame>Up to Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing AEs</measure>
    <time_frame>Up to Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing dose-limiting toxicity (DLTs)</measure>
    <time_frame>Up to Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing grade 1-4 laboratory abnormalities</measure>
    <time_frame>Up to Day 6</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>IDX184 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants will be administered a single 5 mg dose of IDX184.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDX184 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants will be administered a single 10 mg dose of IDX184.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDX184 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants will be administered a single 25 mg dose of IDX184.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDX184 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants will be administered a single 50 mg dose of IDX184.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDX184 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants will be administered a single 75 mg dose of IDX184.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDX184 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants will be administered a single 100 mg dose of IDX184.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy participants will be administered placebo matching IDX184.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDX184</intervention_name>
    <description>IDX184 supplied as size 3, white opaque capsules containing either 5 mg or 25 mg.</description>
    <arm_group_label>IDX184 5 mg</arm_group_label>
    <arm_group_label>IDX184 10 mg</arm_group_label>
    <arm_group_label>IDX184 25 mg</arm_group_label>
    <arm_group_label>IDX184 50 mg</arm_group_label>
    <arm_group_label>IDX184 75 mg</arm_group_label>
    <arm_group_label>IDX184 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo supplied as size 3, white opaque capsules matching IDX184 capsules.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants are in general good health.

          -  All participants of childbearing potential must have agreed to use a consistent form
             of an acceptable double-barrier method of birth control

        Exclusion Criteria:

          -  Participant is pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Zhou XJ, Pietropaolo K, Chen J, Khan S, Sullivan-BÃ³lyai J, Mayers D. Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects. Antimicrob Agents Chemother. 2011 Jan;55(1):76-81. doi: 10.1128/AAC.01101-10. Epub 2010 Nov 8.</citation>
    <PMID>21060109</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>April 22, 2015</last_update_submitted>
  <last_update_submitted_qc>April 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C, healthy volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

